Gouty Arthritis Clinical Trial
Official title:
A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Were Given Canakinumab at the Time of Gout Flare
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06068478 -
A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis
|
Phase 3 | |
| Recruiting |
NCT01867840 -
Role of ASICs in Human Inflammatory Pain
|
N/A | |
| Completed |
NCT05332795 -
The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.
|
N/A | |
| Completed |
NCT05964946 -
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France
|
||
| Terminated |
NCT01362608 -
Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective
|
Phase 3 | |
| Completed |
NCT01626235 -
AMPED Outcomes Registry of Post-ED Pain Management
|
N/A | |
| Not yet recruiting |
NCT04462666 -
Oral Huzhang Granules for Acute Gouty Arthritis
|
Phase 2 | |
| Recruiting |
NCT05658575 -
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
|
Phase 2/Phase 3 |